Is Tazemetostat currently included in medical insurance reimbursement?

Tazemetostat (Tazemetostat) is not currently on the Chinese market, so the drug cannot be purchased directly through domestic channels. If patients need to use the drug, they can usually only purchase it through overseas channels. Since tazetostat is not marketed in China, it has not yet been included in the medical insurance reimbursement system, and patients need to bear higher drug costs.

In overseas markets, the price of original drugs is relatively expensive, especially the American and Japanese versions, which usually cost between 10,000 and 20,000 yuan. This is a big burden for patients, especially if they use drugs for a long time, and it may put a lot of pressure on the economy. Therefore, many patients choose to purchase tazetostat through overseas channels, but they still need to bear higher costs.

In contrast, generic drugs produced in Laos have a greater price advantage, with prices usually around more than 4,000 yuan. Although they are generic drugs, the ingredients of Lao generic drugs are highly consistent with the original drugs, and their efficacy has been certified, making them the choice of some patients. This price difference makes generic drugs a more affordable option, especially for patients with limited financial resources.

Since tazerestat has not yet been marketed in China and has been included in medical insurance, when patients choose whether to use the drug, in addition to considering the efficacy of the drug, they also need to weigh the cost of the drug and whether they can obtain generic drugs through overseas channels. If tazerestat is approved for marketing in China and included in medical insurance in the future, the burden on patients may be effectively reduced.

Reference materials:https://www.tazverik.com/